Edition:
India

Cumberland Pharmaceuticals Inc (CPIX.OQ)

CPIX.OQ on NASDAQ Stock Exchange Global Select Market

6.90USD
1:30am IST
Change (% chg)

$0.17 (+2.53%)
Prev Close
$6.73
Open
$6.75
Day's High
$6.96
Day's Low
$6.75
Volume
2,839
Avg. Vol
4,122
52-wk High
$7.95
52-wk Low
$5.46

Chart for

About

Cumberland Pharmaceuticals Inc. (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company's product portfolio includes Acetadote (acetylcyste... (more)

Overall

Beta: 0.91
Market Cap(Mil.): $112.71
Shares Outstanding(Mil.): 15.90
Dividend: --
Yield (%): --

Financials

  CPIX.OQ Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -0.44 -- --
ROI: -9.27 14.84 14.38
ROE: -10.03 16.34 16.07

BRIEF-Cumberland Pharmaceuticals Expands Into Oncology Support

* CUMBERLAND PHARMACEUTICALS EXPANDS INTO ONCOLOGY SUPPORT Source text for Eikon: Further company coverage:

09 Apr 2018

BRIEF-Cumberland Pharmaceuticals- Entered Agreement With Gastro-Entero Logic To Acquire Assets Associated With Omeclamox((Reg))-Pak

* CUMBERLAND PHARMACEUTICALS-ON MARCH 13, ENTERED AGREEMENT WITH GASTRO-ENTERO LOGIC, LLC TO ACQUIRE ASSETS ASSOCIATED WITH OMECLAMOX -PAK

17 Mar 2018

BRIEF-Cumberland Pharma Q4 Adjusted Earnings Per Share $0.03

* CUMBERLAND PHARMACEUTICALS REPORTS 25% REVENUE GROWTH FOR THE FULL YEAR 2017

07 Mar 2018

BRIEF-Cumberland Pharma Says Data Demonstrates Amifostine Reduces Gastro-Intestinal Toxicity For Multiple Myeloma Patients

* CUMBERLAND PHARMACEUTICALS INC - NEWLY PUBLISHED DATA DEMONSTRATES AMIFOSTINE REDUCES GASTRO-INTESTINAL TOXICITY FOR MULTIPLE MYELOMA PATIENTS Source text for Eikon: Further company coverage:

30 Jan 2018

BRIEF-Cumberland Pharmaceuticals Inc files for mixed shelf of up to $100 million

* Cumberland Pharmaceuticals Inc files for mixed shelf of up to $100 million Source text: (http://bit.ly/2jazuqV) Further company coverage:

08 Nov 2017

BRIEF-Cumberland Pharmaceutical reports Q3 loss per share $0.05

* Cumberland Pharmaceutical reports 27% revenue growth in the third quarter

08 Nov 2017

Earnings vs. Estimates